Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06435936 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo
A Phase 1 study of PHA1A, sponsored by SAb Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06435936 is a Phase 1 study of PHA1A that is active but no longer recruiting, run by SAb Biotherapeutics. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06435936, a Phase 1 study of PHA1A, is active but no longer recruiting, sponsored by SAb Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of an intramuscular injection of SAB-176 intended for use as a pre/post prophylactic for influenza. This is a Phase 1, randomized, double-blind, placebo-controlled clinical trial in which a total of 28 subjects will receive an injection of either SAB-176 or placebo (normal saline). The investigational product will be administered intramuscularly (IM) on Day 1. Four dose escalation cohorts of 7 subjects (5 active and 2 placebo) each are planned. Subjects will be randomized to receive either SAB-176 or placebo in a double-blinded manner. Progression to subsequent dose-escalating cohorts will be dependent on safety measured through Day 5 after dosing of the previous cohort. Blood specimens will be collected at prescribed intervals to examine pharmacokinetics and immunogenicity. Safety will be actively monitored during investigational product administration and for 60 days following dosing. The decision to advance to the next cohort will be based solely on the safety assessment through Day 5. All safety data will be summarized and reviewed by the PI, the Sponsor's Clinical Monitor, and the Research Monitor prior to next cohort dose-escalation.
Conditions Studied
Interventions
- DRUG Single Ascending Dose of SAB-176
- DRUG Single Ascending Dose of Placebo
Study Locations (1)
Maryland
- Naval Medical Research Command (NMRC) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2025-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06435936
The ClinicalTrials.gov registry entry for NCT06435936 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SAb Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PHA1A appearing as the primary indexed condition, and to 2 interventions - of which Single Ascending Dose of SAB-176 is the first listed.
NCT06435936 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06435936 about?
NCT06435936 is a clinical study titled "A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo". This study will evaluate the safety and tolerability of an intramuscular injection of SAB-176 intended for use as a pre/post prophylactic for influenza. This is a Phase 1, randomized, double-blind, placebo-controlled clinical trial in which a total of 28 subjects will receive an injection of either...
What is the current status of trial NCT06435936?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-04-22. Estimated completion is 2025-02-01.
What conditions does trial NCT06435936 study?
This clinical trial studies the following conditions: PHA1A.
What interventions are being tested in trial NCT06435936?
The interventions under investigation include: Single Ascending Dose of SAB-176 (DRUG), Single Ascending Dose of Placebo (DRUG).
Who is sponsoring clinical trial NCT06435936?
This trial is sponsored by SAb Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06435936 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PHA1A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.